Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, sat down to discuss comorbidities newly associated with atopic dermatitis at the 2022 American Academy of Dermatology Annual Meeting.
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, sat down to discuss comorbidities newly associated with atopic dermatitis (AD) at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Transcript
What are some comorbidities now associated with atopic dermatitis that are included in the 2022 AAD Atopic Dermatitis Management Guidelines?
We've had comorbidities that we've known about forever, such as the so-called atopic triad—asthma, food allergies, allergic rhinitis—those are also included in these guidelines. But the newer ones that are a little bit less well known are, for instance, things like bone issues, osteoporosis fractures. That's been a bit of a surprise, and maybe it shouldn't be. Probably multifactorial: is it due to steroid use? Is it due to something else? But that was one.
Probably the one that's most significant, in my own personal opinion—this is not expressed in the guideline—is the issue of depression and anxiety, because obviously that's a huge issue. This document that's been published so far has to do with adults. I see just kids [as a pediatric dermatologist], but that issue of depression and anxiety, risk of suicidal ideation, the association with depression anxiety is associated, was how we labeled that. Association with suicide was less strong because the evidence was less strong. But either way, that's just an important thing to be aware of and to address appropriately within the context of your own experience and your own patient population.
Otherwise, things that were relatively new and quite intriguing were the cardiovascular outcomes. Things like hypertension, associated things like dyslipidemia or obesity, those are important. One of our speakers in the session [Friday], Dr. [Jonathan] Silverberg, who's done a lot of this work himself, referenced atopic dermatitis as a systemic disease. That, for many, is almost a non sequitur, but we are really starting to think of it that way, just like we are starting to think of psoriasis the same way. They're skin manifestations, but there's inflammation that's systemic that can have systemic implications.
Finally, there were things that were less strong in the adult population, like ADHD [attention-deficit/hyperactivity disorder]. That's a stronger literature in the pediatric population, my world, but important to remember, because that's one where you can have a clinical sense of what's going on with a patient and have a really ready explanation. For instance, in my world, kids who are losing focus, have inattention, aren't able to pay attention at school: they have eczema, they're losing sleep, they're tired. Well, maybe they have a separate diagnosis, ADHD, that's treated differently and that would be an important thing to untangle. Same thing with adults; if they're having difficulty at work, staying focused, etc., maybe it's because they're losing sleep with their bad eczema, maybe it's something separate.
Those are, in a nutshell, the ones that I, from a high-level thinker, are worth covering here today, but there were others as well, so I think that document is worth reading.
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Top Pharmacy Leaders to Convene at Asembia’s AXS25 Summit in Las Vegas
April 24th 2025Asembia's AXS25 Summit will unite more than 8000 key decision-makers to explore pharmacy innovation, artificial intelligence, policy, and patient care from April 27 to May 1 at Wynn & Encore in Las Vegas, Nevada.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More